Date: 2016-10-03
Type of information: Establishment of a new subsidiary in the EU
Compound:
Company: Abreos Biosciences (USA - CA) Institut Paoli-Calmettes (France)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration etablishment of a new subsidiary in the EU
Action mechanism:
Disease:
Details: * On October 3, 2016, Abreos Biosciences and the Institut Paoli-Calmettes (IPC) announced a research collaboration to monitor blood levels of biologic drugs, such as monoclonal antibodies, in cancer patients receiving these therapies. This research will accelerate the development of dosing strategies tailored to each patient’s needs with the aim of maximizing clinical benefit, minimizing side effects, and reducing treatment costs. Abreos Biosciences has developed a technology platform, termed Veritope™, for monitoring blood levels of active biologic drug in patients. Abreos France, its recently created French subsidiary, will collaborate with IPC to further understand the clinical implications of pharmacokinetic variability of biologic drugs. With the support of Eurobiomed, Abreos France is establishing itself in Marseille, with a wet lab directly at IPC where researchers and physicians from the Institute will work closely with Abreos. Abreos France is also part of the Onelife cluster, a 5,000sqm structure located near the airport and downtown Marseille, which includes select IT and biotech companies. Dedicated to oncology and rare diseases with the objective of accelerating both R&D and business development of member companies, Onelife will facilitate Abreos’ integration and success in France.
Financial terms:
Latest news:
